Combining Roginolisib with Ruxolitinib for Myelofibrosis Patients Not Responding to JAK Inhibitors

A Phase I/II Open-Label, Multi-centre Study to Assess the Safety and Tolerability of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to an Approved JAK Inhibitors (HEMA-MED)

This study is testing if combining two medications, roginolisib and ruxolitinib, can help adults with myelofibrosis who haven't responded well to other treatments.

Quick facts

• Phase: Phase1; Phase2
• Study type: Interventional
• Enrollment: 26 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: iOnctura (Industry-sponsored)
• Drugs / interventions: ruxolitinib, prednisone
• Locations: 11 sites (Florence, Florence and 10 other locations)
• Trial ID: NCT06887803 on ClinicalTrials.gov

What this trial studies

This clinical trial aims to evaluate the safety and tolerability of roginolisib when used in combination with ruxolitinib in adult patients with myelofibrosis who have not responded adequately to JAK inhibitors. The study is designed as a Phase I/II open-label, single-arm trial, enrolling approximately 26 patients who have been on a stable dose of ruxolitinib for at least 8 weeks. The trial will be conducted in two parts, with the first part assessing the benefit/risk profile of the combination therapy and the second part further characterizing its effects.

Who should consider this trial

Good fit: Ideal candidates for this study are adults over 18 years old with myelofibrosis who have been treated with ruxolitinib for at least 3 months and have not experienced significant spleen reduction.

Not a fit: Patients who have not been treated with ruxolitinib or those who have received other experimental therapies for myelofibrosis may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment combination could provide a new therapeutic option for patients with myelofibrosis who are unresponsive to current JAK inhibitor therapies.

How similar studies have performed: While this approach is novel in combining roginolisib with ruxolitinib, similar studies have shown promise in exploring combination therapies for myelofibrosis.

Eligibility criteria

Inclusion Criteria:

1. ≥18 years of age inclusive, at the time of signing the informed consent.
2. Capable of giving signed informed consent, which includes compliance with the requirements of this protocol.
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
4. Diagnosis of MF, Post-Polycythaemia Vera Myelofibrosis MF (PPV-MF), or post-essential thrombocythemia MF (PET-MF)
5. Dynamic International Prognostic Scoring System (DIPSS) risk category of intermediate-1, intermediate-2, or high
6. Treated with ruxolitinib for ≥ 3 months with a stable dose ≥ 10 mg for a minimum of 8 weeks prior to Day 1. Furthermore, patients must show an unsatisfactory spleen reduction, such as a reduction of less than 25%, and spleen must be palpable ≥ 10 cm below the left costal margin on physical examination
7. Did not receive experimental drug therapy for MF or any other drug considered as an effective treatment for MF (e.g., danazol, hydroxyurea, interferon products) with the exception of ruxolitinib, within 3 months of starting study drug (except in conditions where other effective treatments for MF were completed 6 months prior to starting ruxolitinib)
8. Independent of spleen size, active symptoms of MF at the screening visit, as demonstrated by the presence of a Total Symptom Score (TSS) of ≥ 10 using the Screening Symptom Form.
9. Peripheral blast count \< 10%
10. Act to avoid pregnancy or fathering children based on the criteria below:

    1. Women of non-childbearing potential (i.e., surgically sterile with a hysterectomy and/or bilateral oophorectomy OR ≥ 12 months of amenorrhea and at least 50 years of age).
    2. Women of childbearing potential who had a negative serum pregnancy test at screening and who agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through safety follow-up, at least 1 month after the last dose of study treatment. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the patient and their understanding confirmed.
    3. Men who agree to take appropriate precautions to avoid fathering from screening through safety follow-up, at least 1 month after the last dose of study treatment. Permitted methods that are at least 99% effective in preventing pregnancy (see Appendix 3) should be communicated to the patient and their understanding confirmed.

Exclusion Criteria:

1. Inability to swallow food or any condition of the upper gastrointestinal tract that precludes administration of oral medications.
2. History of a prior Grade 3 or 4 AE which did not respond to therapy or resolved with treatment interruptions and returned to at least Grade 1, other than fatigue. Note: Patients with ≤ Grade 2 neuropathy or alopecia are an exception and may enrol.
3. Active autoimmune process (e.g., rheumatoid arthritis, moderate or severe psoriasis, multiple sclerosis, inflammatory bowel disease, immune colitis) for which systemic treatment (i.e., use of disease-modifying agents, corticosteroids, or immunosuppressive drugs) is required. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
4. History or presence of an abnormal ECG that, in the Investigator's opinion, is clinically meaningful. Screening QTc interval \> 480 milliseconds is excluded (corrected by Fridericia). In the event that a single QTc is \> 480 milliseconds, the patient may enrol if the average QTc for the 3 ECGs is \< 480 milliseconds. For patients with an intraventricular conduction delay (QRS interval \> 120 msec), the JTc interval may be used in place of the QTc with Sponsor approval. The JTc must be \< 340 milliseconds if JTc is used in place of the QTc. Patients with left bundle branch block are excluded.
5. Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (\< 6 months prior to enrolment), myocardial infarction (\< 6 months prior to enrolment), unstable angina, congestive heart failure (≥ New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.
6. Patients with active malignancy requiring concurrent intervention or previous malignancies unless a complete remission was achieved at least 2 years prior to study entry and no additional therapy is required during the study period and the patient is assessed at low risk of relapse by the investigator. Note: Patients with a slow progressing cancer (e.g. prostate) or an in situ cancers (e.g. cervical dysplasia) are permitted.
7. Any serious or uncontrolled medical disorder or active infection that, in the opinion of the Investigator, may increase the risk associated with study participation, study drug administration, or would impair the ability of the patient to receive protocol therapy.
8. Use of the following treatments within the time periods noted:

   1. Erythropoiesis stimulating agent (ESA) within 4 weeks prior to start of roginolisib.
   2. Splenic irradiation within 3 months prior to start of roginolisib.
9. Major surgery within 2 weeks of the first dose of study drug (minimally invasive procedures such as bronchoscopy, bone marrow biopsy, insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery and are not exclusionary)
10. Receiving an immune-suppressive based treatment for any reason (including chronic use of systemic corticosteroid at doses \> 10 mg/day prednisone equivalent) within 14 days prior to the first dose of study treatment. Use of inhaled or topical steroids (including but not limited to creams or intra-articular injection) or brief corticosteroid use for radiographic procedures or systemic corticosteroids ≤ 10 mg is permitted.
11. Have received a live vaccine within 30 days of planned start of study therapy while on trial. Other type of vaccines, including SARS-Co2 vaccines, are allowed.
12. Known allergy or reaction to any component of either study drugs or formulation components.
13. Currently breastfeeding.
14. Known alcohol or other substance abuse.
15. Laboratory and medical history parameters not within Protocol-defined range.

    1. Absolute neutrophil count \< 1.5 × 109/L.
    2. Platelet count \< 100 × 109/L.
    3. Haemoglobin \< 8 g/dL (transfusion is acceptable to meet this criterion).
    4. Serum creatinine ≥ 1.5 × institutional ULN or measured or calculated creatinine clearance (glomerular filtration rate can also be used in place of creatinine or CrCl) \< 50 mL/min for patients with creatinine levels \> 1.5 × institutional ULN.
    5. Aspartate aminotransferase (AST) or Alanine transaminase (ALT) ≥ 2.5 × ULN in the absence of hepatic metastases or ≥ 5 × ULN with hepatic metastases at screening.
    6. Total bilirubin ≥ 1.2 × ULN are excluded unless direct bilirubin is ≤ ULN. If there is no institutional ULN, then direct bilirubin must be \< 40% of total bilirubin to be eligible (except patients with Gilbert syndrome, who must have total bilirubin \< 51.3 μmol/L).
    7. International normalized ratio or prothrombin time (PT) \> 1.5 × ULN.
    8. Activated partial thromboplastin time (aPTT) \> 1.5 × ULN.
    9. Evidence of acute infection of hepatitis B virus (HBV), (for example: positive for HBsAg, anti-HBc, IgM anti-HBc and negative for anti-HBs), hepatitis C virus (HCV) (for example: HCV antibody reactive; HCV RNA detected) and HIV.

    Patients who are on stable antiviral therapy, in good clinical control (ie for HIV a viral load \< 400 copies/mL and a CD4+ count of ≥ 350 cells/uL) AND asymptomatic are eligible for the study
16. Presence of active or inactive 'latent' tuberculosis.

Where this trial is running

Florence, Florence and 10 other locations

• Azienda Ospedaliero Universitaria Careggi Firenze, Struttura Complessa di Ematologia — Florence, Florence, Italy (Recruiting)
• IRCCS Clinical Institute Humanitas — Rozzano, Milan, Italy (Recruiting)
• Istituto di Ematolgia e Oncologia Medica — Bologna, Italy (Recruiting)
• Azienda Sanitario Universitaria Friuli Centrale — Udine, Italy (Recruiting)
• Vall d'Hebron University Hospital — Barcelona, Spain (Recruiting)
• Avigunda Gran via de l'Hospitalet 199-203, 08908 L'Hospitalet de Llobregat — Barcelona, Spain (Recruiting)
• START Madrid CIOCC — Madrid, Spain (Not_yet_recruiting)
• Hospital Universitario de Salamanca — Salamanca, Spain (Recruiting)
• United Lincolnshire Teach Hospitals NHS Trust, Pilgrim Hospital Boston — Boston, Lincolnshire, United Kingdom (Not_yet_recruiting)
• Belfast City Hospital — Belfast, United Kingdom (Not_yet_recruiting)
• Guy´s and St. Thomas NHS Foundation Trust — London, United Kingdom (Not_yet_recruiting)

Study contacts

• Study coordinator: Tracey Hammett, RN

Conditions Myelofibrosis